A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway Translational Blockade of Immune Checkpoints

By Li Yongshu   Li Fangfei   Jiang Feng   Lv Xiaoqing   Zhang Rongjiang   Lu Aiping   Zhang Ge  

International Journal of Molecular Sciences, Vol. 17, Iss. 7, 2016-07 ,pp. : 1151-1151

MDPI

Access to resources Recommend Favorite

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

By Tunger Antje   Kießler Maximilian   Wehner Rebekka   Temme Achim   Meier Friedegund   Bachmann Michael   Schmitz Marc  

Biomedicines, Vol. 6, Iss. 1, 2018-03 ,pp. : 26-26

MDPI

Access to resources Recommend Favorite

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types

By Scognamiglio Giosuè   De Chiara Anna   Di Bonito Maurizio   Tatangelo Fabiana   Losito Nunzia Simona   Anniciello Annamaria   De Cecio Rossella   D’Alterio Crescenzo   Scala Stefania   Cantile Monica   Botti Gerardo  

International Journal of Molecular Sciences, Vol. 17, Iss. 5, 2016-05 ,pp. : 790-790

MDPI

Access to resources Recommend Favorite

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

By Šmahel Michal  

International Journal of Molecular Sciences, Vol. 18, Iss. 6, 2017-06 ,pp. : 1331-1331

MDPI

Access to resources Recommend Favorite

Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice

By Rom-Jurek Eva-Maria   Kirchhammer Nicole   Ugocsai Peter   Ortmann Olaf   Wege Anja K.   Brockhoff Gero  

International Journal of Molecular Sciences, Vol. 19, Iss. 2, 2018-02 ,pp. : 563-563

MDPI

Access to resources Recommend Favorite